Scinopharm Taiwan, Ltd. Statistics
Scinopharm Taiwan, Ltd. (1789) Stock Statistics & Valuation Metrics
Total Valuation
Scinopharm Taiwan, Ltd. has a market cap or net worth of TWD 15.93B. The enterprise value is TWD 13.70B.
- Market Cap
- TWD 15.93B
- Enterprise Value
- TWD 13.70B
Share Statistics
Scinopharm Taiwan, Ltd. has 790,739,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 790,739,200
- Owned by Insiders
- ―
- Owned by Institutions
- 1.10%
Financial Efficiency
Scinopharm Taiwan, Ltd.’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 0.90%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 0.90%
- Return on Capital Employed (ROCE)
- 0.01
- Revenue Per Employee
- 3.13M
- Profits Per Employee
- 135.60K
- Employee Count
- 1,010
- Asset Turnover
- 0.27
- Inventory Turnover
- 1.26
Valuation Ratios
The current PE Ratio of Scinopharm Taiwan, Ltd. is 943.44. Scinopharm Taiwan, Ltd.’s PEG ratio is -10.39.
- PE Ratio
- 943.44
- PS Ratio
- 5.42
- PB Ratio
- 1.85
- Price to FCF
- 28.58
- Price to Operating Cash Flow
- 24.04
- PEG Ratio
- -10.39
Income Statement
In the last 12 months, Scinopharm Taiwan, Ltd. had revenue of 3.16B and earned 136.95M in profits. Earnings per share was 0.17.
- Revenue
- 3.16B
- Gross Profit
- 1.10B
- Operating Income
- 108.91M
- Pretax Income
- 147.38M
- Net Income
- 136.95M
- EBITDA
- 673.97M
- Earnings Per Share (EPS)
- 0.17
Cash Flow
In the last 12 months, operating cash flow was 805.65M and capital expenditures -228.79M, giving a free cash flow of 576.85M billion.
- Operating Cash Flow
- 805.65M
- Free Cash Flow
- 576.85M
- Free Cash Flow per Share
- 0.62
Dividends & Yields
Scinopharm Taiwan, Ltd. pays an annual dividend of ―, resulting in a dividend yield of 1.44%
- Dividend Per Share
- ―
- Dividend Yield
- 1.44%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.50%
- Earnings Yield
- 0.09%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- 16.14%
- 50-Day Moving Average
- 19.17
- 200-Day Moving Average
- 20.02
- Relative Strength Index (RSI)
- 58.15
- Average Volume (3m)
- 493.36K
Important Dates
Scinopharm Taiwan, Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Scinopharm Taiwan, Ltd. as a current ratio of 7.74, with Debt / Equity ratio of 7.25%
- Current Ratio
- 7.74
- Quick Ratio
- 5.43
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -3.48
- Interest Coverage Ratio
- 11.04
Taxes
In the past 12 months, Scinopharm Taiwan, Ltd. has paid 10.42M in taxes.
- Income Tax
- 10.42M
- Effective Tax Rate
- 0.07
Enterprise Valuation
Scinopharm Taiwan, Ltd. EV to EBITDA ratio is 46.59, with an EV/FCF ratio of 24.03.
- EV to Sales
- 4.56
- EV to EBITDA
- 46.59
- EV to Free Cash Flow
- 24.03
- EV to Operating Cash Flow
- 17.21
Balance Sheet
Scinopharm Taiwan, Ltd. has TWD 3.50B in cash and marketable securities with TWD 873.09M in debt, giving a net cash position of TWD 2.63B billion.
- Cash & Marketable Securities
- TWD 3.50B
- Total Debt
- TWD 873.09M
- Net Cash
- TWD 2.63B
- Net Cash Per Share
- TWD 3.32
- Tangible Book Value Per Share
- TWD 12.03
Margins
Gross margin is 27.54%, with operating margin of -3.67%, and net profit margin of 0.55%.
- Gross Margin
- 27.54%
- Operating Margin
- -3.67%
- Pretax Margin
- -0.89%
- Net Profit Margin
- 0.55%
- EBITDA Margin
- 9.79%
- EBIT Margin
- -3.05%
Analyst Forecast
The average price target for Scinopharm Taiwan, Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -4.75%
- EPS Growth Forecast
- -90.91%
